Walter Wenninger Nominated for Election as New Supervisory Board Member of Evotec

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ:
EVTC) announced today that the Supervisory Board proposes at the next
Annual General Meeting to be held on June 4, 2009 the election of Dr
Walter Wenninger as new member of the Company's Supervisory Board. He
will replace John Walker who decided not to make himself available
for nomination again due to other commitments. All other current
Supervisory Board members will be proposed for re-election.

Dr Wenninger has profound experience in strategic management,
research & development and sales & marketing from leading positions
in the international pharmaceutical industry. His career includes
more than 30 years at Bayer AG where he held top-executive management
positions within the lifescience business in Europe and the United
States. From 1994 to 2000 Dr Wenninger served as a member of the
Management Board of Bayer AG responsible for the healthcare sector.
Following his retirement at Bayer, he has been involved in corporate
development of several life science organizations. He is a member of
the Executive Committee of the German Cardiac Research Foundation,
the Executive Committee of the Robert-Koch-Foundation, and was a
longtime member of the Board of Trustees of the German Cancer
Research Center. Dr Wenninger currently serves on the boards of
various other European pharmaceutical and biotechnology companies
including Noxxon Pharma AG, Paion AG, Recordati S.p.A. and Santaris
Pharma A/S.

Dr Werner Lanthaler, Chief Executive Officer of Evotec AG, said: "We
are delighted that we were able to attract Dr Wenninger as a new
member for Evotec's Supervisory Board. Evotec will greatly benefit
from his international industry background and his experience in
strategic reorganizations. On behalf of Evotec I would also like to
thank John Walker very much for his great support and work especially
in the process of integrating our US operations following the
acquisition of Renovis in May 2008."

Contact: Dr Werner Lanthaler, Chief Executive Officer,
Evotec AG, Tel.: +49.(0)40.56081-242, werner.lanthaler@evotec.com

Contact: Anne Hennecke, Senior Vice President, Investor Relations &
Corporate Communications, Evotec AG, Phone: +49.(0)40.56081-286,
anne.hennecke@evotec.com

Forward-Looking Statements
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. Such
forward-looking statements include, but are not limited to,
statements about our expectations and assumptions concerning future
reductions in operating expenses and cash burn, regulatory, clinical
and business strategies, the progress of our clinical development
programs and timing of the results of our clinical trials, strategic
collaborations and management's plans, objectives and strategies.
These statements are neither promises nor guarantees, but are subject
to a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. In
particular, the risks and uncertainties include, among other things:
risks that product candidates may fail in the clinic or may not be
successfully marketed or manufactured; risks relating to our ability
to advance the development of product candidates currently in the
pipeline or in clinical trials; our inability to further identify,
develop and achieve commercial success for new products and
technologies; competing products may be more successful; our
inability to interest potential partners in our technologies and
products; our inability to achieve commercial success for our
products and technologies; our inability to protect our intellectual
property and the cost of enforcing or defending our intellectual
property rights; our failure to comply with regulations relating to
our products and product candidates, including FDA requirements; the
risk that the FDA may interpret the results of our studies
differently than we have; the risk that clinical trials may not
result in marketable products; the risk that we may be unable to
successfully secure regulatory approval of and market our drug
candidates; and risks of new, changing and competitive technologies
and regulations in the U.S. and internationally.

The list of risks above is not exhaustive. Our most recent Annual
Report on Form 20-F, filed with the Securities and Exchange
Commission, and other documents filed with, or furnished to the
Securities and Exchange Commission, contain additional factors that
could impact our businesses and financial performance. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in
our expectations or any change in events, conditions or circumstances
on which any such statement is based.

--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480; ISIN:
DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All
Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Düsseldorf,
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt
in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.